SSG XXV: The Stop-GIST Trial; Discontinuation of Imatinib in Patients With Oligo-metastatic GIST

Study ID
NCT02924714

Study type
Interventional

Study phase
Not Applicable

Study status
Suspended

Trial Acronym

Trial Summary

The trial "The stop-GIST trial" is an Oslo University Hospital sponsored, prospective, open-label, 1-group, multicenter phase II trial evaluating discontinuation of imatinib in highly selected patients treated with imatinib longer than 5 years for oligo-metastatic GIST (≤ 3 metastases) and who have no detectable overt GIST lesions on CT/MRI imaging following complete surgical resection (R0/R1-resection) or radiofrequency ablation (RFA) of the metastases.

More informations

Trial Starting Date

Jan 31,2017

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit